

on claim 5 only. Claims 21-25 are added. Support for the new claims can be found throughout the specification as originally filed. Specifically, support for claim 21 can be found at page 8 lines 16-26, page 9 lines 1-5, Examples 2-4 and Figures 3-5. The specification at the cited locations describes that lactoferrin inhibits dermal inflammatory response that is characterized by accumulation of dendritic cells in lymph nodes, by reducing the accumulation of dendritic cells in the lymph nodes. The recitation of "allergen" in claim 22 is also supported by the indicated disclosure. The inclusion of an inflammatory response mediated by "TNF- $\alpha$ " or characterized by "Langerhans cell migration" in claims 23 and 24, respectively, is supported by the entire specification, and more specifically by description of Example 3. The inflammatory disorders recited in claim 25 are supported by the description at page 4 lines 10-15.

An issue of new matter is not raised, and entry of the claim amendments is respectfully requested. Upon entry of this Amendment, claims 5-10, 12-14, and 21-25 are now pending.

Applicants hereby respectfully request reconsideration of the application and allowance of the claims in view of the preceding amendments. Applicants also urge the Examiner to consider the arguments presented in the February 27, 2001 amendment that is not entered. Attached hereto is a copy of the "Version with Markings to Show Changes Made."

### **III. CONCLUSION**

In view of the amendments and remarks Applicants assert that the specification and claims comport with all of the requirements of 35 USC §103, and Applicants request an early notice of allowance. However, if the Office believes there are any outstanding matters to be resolved, she is invited to telephone the undersigned at the telephone number listed below.


In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 08-3038** referencing docket no. **00138.0041**.

However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Date: April 9, 2001

  
Albert P. Halluin, (Reg. No. 25,227)  
Karen K. Wong, (Reg. No. 44,409)

**HOWREY, SIMON, ARNOLD & WHITE**  
301 Ravenswood Avenue  
Box 34  
Menlo Park, CA 94025  
(650) 463-8100



**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the claims:**

Claims 1-4 and 19-20 have been cancelled without prejudice and disclaimer.

Claims 7-10 and 12-14 have been amended as follows:

7. (Twice Amended) The method according to ~~{any one of claims 1, and 5}~~ claim 5 wherein the allergen-induced inflammatory disorder features a local immune response characterized by increased production of TNF- $\alpha$ .

8. (Twice Amended) The method according to ~~{any one of claims 1, and 5}~~ claim 5 wherein the lactoferrin product is a naturally occurring lactoferrin.

9. (Twice Amended) The method according to ~~{any one of claims 1, and 5}~~ claim 5 wherein the lactoferrin product is a recombinantly produced lactoferrin or a biologically active analog thereof.

10. (Twice Amended) The method according to ~~{any one of claims 1, and 5}~~ claim 5 wherein the lactoferrin product is a biologically active fragment of lactoferrin.

12. (Twice Amended) The method according to ~~{any one of claims 1, and 5}~~ claim 5 wherein the inflammatory disorder is a dermal inflammatory disorder.

13. (Twice Amended) The method according to ~~{any one of claims 1, and 5}~~ claim 5 wherein the inflammatory disorder is selected from the group consisting of contact dermatitis, psoriasis, UV-induced inflammation, infant diaper rash, and acne.



14. (Twice Amended) The method according to ~~{any one of claims 1, and 5}~~  
claim 5 wherein the lactoferrin product is administered in a composition further  
comprising an anti-wrinkle agent and the inflammatory disorder is facial skin aging.

New claims 21-25 have been added:

21. (New) A method of inhibiting in a mammal a dermal inflammatory response that is characterized by accumulation of dendritic cells in lymph nodes, comprising administering to the mammal a pharmaceutically effective amount of lactoferrin product that reduces the accumulation of dendritic cells in the lymph nodes.
22. (New ) The method of claim 21, wherein the dermal inflammatory response is induced by an allergen.
23. (New) The method of claim 21, wherein the dermal inflammatory response is mediated by TNF- $\alpha$ .
24. (New) The method of claim 21, wherein the dermal inflammatory response is further characterized by Langerhans cell migration.
25. (New) The method of claim 21, wherein the dermal inflammatory response is manifested as a disorder selected from the group consisting of contact dermatitis, psoriasis, UV-induced inflammation, skin aging, infant diaper rash, and acne.